Non-invasive Coronary Imaging Market Size, Share & Trends Analysis Report By Modality (Radionuclide Imaging, Echocardiography, CAT, CMR), By End-use, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global non-invasive coronary imaging market size was valued at USD 0.142 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 6.8% from 2023 to 2030. Cardiovascular disease (CVD) is regarded as the main cause of death across the globe. According to the Centers for Disease Control and Prevention, nearly USD 230 billion was required to treat heart disease in 2018, in the U.S. Additionally, according to WHO, CAD killed approximately 38,000 people in 2020 in the U.S. and 17.9 million deaths worldwide.

To curb the increase in the death total, the U.S. government invested ~1% of its GDP exclusively in the diagnosis and treatment of CVD. Prevalence rates of CVD in France, Spain, and Italy are the highest in Europe. It ranged from 25% to 36% per 10,000 population. The need to develop efficient diagnostic tools with reduced turnaround time, the increased need to reduce radiologists’ burden, the rising need to reduce diagnosis cost, and the need to avoid unnecessary complications arising from invasive detection techniques, are the factors influencing the noninvasive coronary imaging industry’s growth.

Computed Tomography Angiography is the best and most accurate test for the diagnosis of coronary heart disease according to NHS, U.K. However, numerous clinical trials suggest that PET scans hold improved diagnostic accuracy as compared to all other imaging modalities. However, the lack of reliable and guaranteed clinical trial data and lack of funds to develop noninvasive diagnostic tools are creating a barrier to market growth.

The COVID-19 pandemic negatively affected the market due to the drop in research activity, the closure of academic institutions, and a drop in clinical trial activity at hospitals and diagnostic centers. Any diagnostic or surgical procedures in end-user settings were also discouraged due to the threat of virus propagation. Due to financial constraints, hospitals, diagnostic facilities, and clinics adopted fewer non-invasive diagnostic software and systems. As a result, the market witnessed a decline in 2020.

Modality Insights

The radionuclide cardiac imaging segment is expected to grow at the highest CAGR of 7.15% over the forecast period. Factors such as non-invasiveness, clarity of image, accurate detection of disease even at a nascent stage, reduced isotope doses, optimized acquisition geometry, collimator design, shorter image capture time, and increasing adoption among end-users, influence the growth. Studies published in the National Centre for Biotechnology Information stated that PET perfusion stress test imaging can be effectively performed at lower doses (<4 mSv) than that of SPECT, with precise images, obtained using PET/CT scanners.

Cardiac CT accounted for a share of ~30% in this segment due to its high sensitivity, specificity, positive and negative predictive value, precise detection of non-obstructive coronary atheroma, and ability to identify additional adverse plaque characteristics, which enables CTA to be the first non-invasive imaging choice by end-users. Thus, the CTA market is expected to grow in the forecast period to reach USD 73.75 million in 2030 from USD 42.58 million by 2022.

End-use Insights

Research institute accounted for the largest share of ~87.5% in 2022. The increased need to develop efficient, accurate, and non-invasive detection techniques to diagnose myocardia, ischemia, and numerous other cardiac disorders, has influenced the market growth. Researchers at King’s College London rigorously research for 8 consecutive years since 2012 to fully develop a functioning CMRA technology. This technology doesn’t require any catheterization, zero need for dose injection of contrast media, and no patient exposure to harmful ionization radiation.

Additionally, this technique addresses the limitations of current CMRA protocols which suffered from long and unpredictable scan times. This system has saved radiologists time in the U.K. and eased their burden to fulfill their ~100k cardiac MRI scans. Thus, research in this market holds a large scope, influencing the market share of the research institute segment. On the other hand, numerous clinical trials are conducted in hospitals and diagnostic centers to determine the clinical accuracy of these systems, influencing its high growth rate of ~7.2% over the forecast period.

The pharmaceutical and biotechnology companies segment is also anticipated to witness a significant CAGR over the forecast period. Near-infrared imaging is used in pharmaceutical companies to measure the critical material attributes of a product. They are used in pharmaceutical and biotechnology companies for the identification of raw materials, verification of the quality of lyophilized materials, monitoring coating and content of tablets, monitoring fermentation and cell culture, and various in-line and on-line process monitoring.

Regional Insights

North America held the dominant revenue share of 45.7% in 2022 owing to the presence of technologically sound medical staff, improved healthcare expenditure by the government, a rise in the number of cancer cases, an increase in obesity ratio compared to other nations, and increased research and developmental activities.

However, Asia Pacific is said to witness the highest CAGR of 7.1% during the forecast period due to increased research activities to develop new systems, improved government investment in healthcare, and high demand for advanced imaging devices. This provides the price-sensitive and unpenetrated market with a large scope for growth.

Key Companies & Market Share Insights

Companies like GE Healthcare; Toshiba; Hologic Inc.; Carestream Health Inc.; and Siemens Healthineers are the top players in this market. These companies are investing in product launches and conducting clinical trials to determine the clinical efficacy of these systems. For instance, GE Healthcare conducted a multicenter Syntax III revolution trial that studied the efficacy of invasive vs noninvasive CT for cardiac imaging. The results published in 2019, stated that noninvasive techniques greatly eased patient care and improved the treatment adopted by care providers. Some prominent players in the non-invasive coronary imaging market include:

• Toshiba Medical Systems

• Hologic, Inc.

• Carestream Health, Inc.

• GE Healthcare

• Siemens Healthcare

• Philips Healthcare

• Hitachi Medical Corporation

Non-invasive Coronary Imaging Market Report Scope

Global Non-invasive Coronary Imaging Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global non-invasive coronary imaging market report based on modality, end-use, and region:

• Modality Outlook (Revenue, USD Million, 2018 - 2030)

  • Radionuclide Cardiac Imaging

  • Echocardiography

  • Cardiac Computed Tomography

  • Cardiac Magnetic Resonance Imaging

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Diagnostic Imaging Centers

  • Research Institute

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Spain

    • Italy

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE